William Blair & Company
SRPT icon

William Blair & Company’s Sarepta Therapeutics SRPT Stock Holding History

William Blair & Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$7K – 1633
2018
Q1 		$7K Hold
100
– – ﹤0.01% 1474
2017
Q4 		$6K Buy
+100
New +$5.3K ﹤0.01% 1360

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

William Blair & Company's SRPT Position: Q2 2026 in Review

William Blair & Company reduced its Sarepta Therapeutics (SRPT) stake by 4% in Q2 2026, selling an estimated $19.6K and leaving 24,654 shares worth $443K. The position accounts for ﹤0.01% of the portfolio, ranked #1276.

William Blair & Company first reported a position in SRPT in Q2 2013 and has held it in 41 quarters since. The position peaked at $27.5M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • William Blair & Company held 24,654 shares of Sarepta Therapeutics worth $443K as of Q2 2026.
  • William Blair & Company sold 1,036 Sarepta Therapeutics shares in Q2 2026, an estimated $19.6K.
  • Sarepta Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1276 holding.
  • William Blair & Company first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 41 quarters since.
  • William Blair & Company's Sarepta Therapeutics position peaked at $27.5M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.